Ensign Peak Advisors’s BeOne Medicines Ltd ONC Stock Holding History

Ensign Peak Advisors’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-3,300	Closed	-$445K	–	2253
2022 Q3	$445K	Hold	3,300	–	–	﹤0.01%	1522
2022 Q2	$534K	Hold	3,300	–	–	﹤0.01%	1432
2022 Q1	$622K	Hold	3,300	–	–	﹤0.01%	1460
2021 Q4	$894K	Hold	3,300	–	–	﹤0.01%	1356
2021 Q3	$1.2M	Hold	3,300	–	–	﹤0.01%	1366
2021 Q2	$1.13M	Buy	3,300 +200	+6%	+$66.2K	﹤0.01%	1398
2021 Q1	$1.08M	Buy	3,100 +2,300	+288%	+$762K	﹤0.01%	1403
2020 Q4	$207K	Sell	800 -850	-52%	-$234K	﹤0.01%	1719
2020 Q3	$473K	Sell	1,650 -200	-11%	-$47K	﹤0.01%	1545
2020 Q2	$349K	Hold	1,850	–	–	﹤0.01%	1522
2020 Q1	$228K	Hold	1,850	–	–	﹤0.01%	1517
2019 Q4	$307K	Buy	+1,850	New	+$307K	﹤0.01%	1590

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

CII

Capital International Inc Los Angeles, California $14.3B AUM 34.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Ensign Peak Advisors's ONC Position: Q4 2022 in Review

Ensign Peak Advisors sold out of BeOne Medicines Ltd (ONC) in Q4 2022, closing a stake of 3,300 shares — an estimated $445K sold.

Ensign Peak Advisors first reported a position in ONC in Q4 2019 and held it in 12 quarters. The position peaked at $1.2M in Q3 2021. 212 funds tracked by Wall St. Rank hold ONC as of Q4 2022.

Ensign Peak Advisors reported no remaining BeOne Medicines Ltd position as of Q4 2022 after selling out during the quarter.
Ensign Peak Advisors sold 3,300 BeOne Medicines Ltd shares in Q4 2022, an estimated $445K.
Ensign Peak Advisors first reported a position in BeOne Medicines Ltd in Q4 2019 and held it in 12 quarters.
Ensign Peak Advisors's BeOne Medicines Ltd position peaked at $1.2M in Q3 2021.
212 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.